NCT02744625

Completed

Phase 4

Physiologic Study of Cerebral Perfusion

Centre de recherche du Centre hospitalier universitaire de Sherbrooke1 site in 1 country22 target enrollmentApril 2016

ConditionsCerebral Perfusion Pressure Vasopressor Agents Shock Magnetic Resonance Imaging (MRI), Functional

InterventionsLower doses of vasopressor therapy for a MAP of 65 mmHg Propofol for light sedation Higher doses of vasopressor therapy for a MAP of 75 mmHg

DrugsHigher doses of vasopressor therapy for a MAP of 75 mmHg Lower doses of vasopressor therapy for a MAP of 65 mmHg Propofol for light sedation

Overview

Phase: Phase 4
Intervention: Lower doses of vasopressor therapy for a MAP of 65 mmHg
Conditions: Cerebral Perfusion Pressure
Sponsor: Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Enrollment: 22
Locations: 1
Primary Endpoint: Global and regional cerebral blood flow
Status: Completed
Last Updated: 9 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The aim of the study is to measure cerebral perfusion using MRI in healthy subjects (with and without sedation) and in vasopressor-dependent patients

Registry

clinicaltrials.gov

Start Date

April 2016

End Date

March 2017

Last Updated

9 years ago

Study Type

Interventional

Study Design

Crossover

Sex

All

Investigators

Sponsor

Centre de recherche du Centre hospitalier universitaire de Sherbrooke

Responsible Party

Principal Investigator

François Lamontagne

Clinician Scientist

Université de Sherbrooke

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Arms & Interventions

Shock lower Mean Arterial Pressure (MAP)

Vasopressor-dependent treated to lower MAP (65 mmHg)

Intervention: Lower doses of vasopressor therapy for a MAP of 65 mmHg

Shock lower Mean Arterial Pressure (MAP)

Vasopressor-dependent treated to lower MAP (65 mmHg)

Intervention: Propofol for light sedation

Shock higher MAP

Vasopressor-dependent treated to higher MAP (75 mmHg)

Intervention: Higher doses of vasopressor therapy for a MAP of 75 mmHg

Shock higher MAP

Vasopressor-dependent treated to higher MAP (75 mmHg)

Intervention: Propofol for light sedation

Healthy participant sedated

Healthy participant Under light sedation

Intervention: Propofol for light sedation

Outcomes

Primary Outcomes

Global and regional cerebral blood flow

Time Frame: Within 15 minutes of intervention initiation

Cerebral blood flow will be measured by the arterial spin labeling technique (ASL) which provides information expressed in mL/100g/min. Using 3-T MRI technology,we will first acquire T1 images of the brain and sub-regions of interest. Thereafter, ASL sequences will be acquired in contiguous slices. The procedure will be followed on sedation and off sedation for healthy volunteers (in random order) and at mean arterial pressure of 65 mmHg and 75 mmHg (in random order) in patients receiving vasopressor therapy.